July 22nd, 2019
•Here, we present a protocol to genetically edit CAR-T cells via a CRISPR/Cas9 system.
Related Videos
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
A Spheroid Killing Assay by CAR T Cells
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor (CAR) T Cell Infusions in Mice
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved